The problem of anti-pig antibodies in pig-to-primate xenografting: Current and novel methods of depletion and/or suppression of production of anti-pig antibodies

Xenotransplantation

Volumn 6, Issue 3, 1999, Pages 157-168

  Alwayn, Ian P J ^a   Basker, Murali ^a   Buhler, Leo ^a   Cooper, David K C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Anti Gal antibodies; Anti CD40 Ligand monoclonal antibody; B cells; Pig to primate; Tolerance; Xenotransplantation

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD20 ANTIBODY; CD22 ANTIBODY; CLADRIBINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIGOSACCHARIDE; RITUXIMAB; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANIMAL CELL; ANTIGEN ANTIBODY REACTION; CONTROLLED STUDY; GRAFT REJECTION; IMMUNOADSORPTION; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; SWINE; WHOLE BODY RADIATION; XENOTRANSPLANTATION;

ANIMALS; ANTIBODY FORMATION; DISACCHARIDES; EPITOPES; GRAFT REJECTION; GRAFT SURVIVAL; ORGAN TRANSPLANTATION; PRIMATES; SWINE; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032871066     PISSN: 0908665X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3089.1999.00030.x     Document Type: Review

References (92)

1. PERPER RJ, NAJARIAN J. Experimental renal heterotransplantation. I. In widely divergent species. Transplantation 1966; 4: 377.
2. GALILI U, SHOHET SB, KOBRIN E, et al. Man, apes and Old World monkeys differ from other mammals in the expression of α-galactosyl epitopes on nucleated cells J Biol Chem 1988; 263: 17755.
3. GALILI U, RACHMILEWITZ EA, PELEG A, et al. A unique natural human IgG antibody with anti-α-galactosyl specificity J Exp Med 1984; 260: 1519.
4. GOOD AH, COOPER DKC, MALCOLM AJ, et al. Identification of carbohydrate structures that bind human anti-porcine antibodies: implications for discordant xenografting in humans. Transplant Proc 1992; 24: 559.
5. COOPER DKC, GOOD AH, KOREN E, et al. Identification of α-galatosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transplant Immunol 1993; 1: 198.
6. COOPER DKC, KOREN E, ORIOL R. Oligosaccharides and discordant xenotransplantation. Immunol Rev 1994; 141: 31.
7. KOREN E, NEETHLING FA, RICHARDS S, et al. Binding and specificity of major immunoglobulin classes of preformed human anti-pig heart antibodies. Transplant Int 1993; 6: 351.
8. KUJUNDZIC M, KOREN E, NEETHLING FA, et al. Variability of anti-αGal antibodies in human serum and their relation to serum cytotoxicity against pig cells. Xenotransplantation 1994; 1: 58.
9. GALILI U, MANDRELL RE, HAMADEH RM, et al. The interaction between the human anti-α-galactosyl IgG (anti-Gal) and bacteria of the human flora. Infect Immun 1988; 57: 1730.
10. SANDRIN MS, VAUGHAN HA, DABKOWSKI PL, et al. Antipig IgM antibodies in human serum react predominantly with Galα(1-3) Gal epitopes. Proc Natl Acad Sci USA 1993; 90: 11391.
11. GALILI U. Interaction of the natural anti-Gal antibody with agalactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 1993; 14: 480.
12. GALILI U. Anti-agalactosyl (anti-Gal) antibody damage beyond hyperacute rejection. In: COOPER DKC, KEMP E, PLATT JL, WHITE DJG, eds. Xenotransplantation, 2nd edn. Heidelberg: Springer 1997.
13. BACH FH, ROBSON SC, WINKLER H, et al. Barriers to xenotransplantation. Nature Med 1995; 1: 869.
14. ORIOL R, Ye Y, KOREN E, et al. Carbohydrate antigens of pig tissues reacting with human natural antibodies as potential targets for hyperacute vascular rejection in pig-to-man organ xenotransplantation Transplantation 1993; 56: 1433.
15. ORIOL R, BARTHOLD F, BERGEMER A-M, et al. Monomorphic and polymorphic carbohydrate antigens on pig tissues: Implications for organ xenotransplantation in the pig-to-man model. Transplant Int 1994; 7: 405.
16. COOPER DKC. Xenoantigens and xenoantibodies. Xenotransplantation 1998; 5: 6.
17. MCMORROW IM, COMRACK CA, NAZAREY PP, et al. Relationship between ABO blood group and levels of Gal alpha,3galactose-reactive human immunoglobulin G. Transplantation 1997; 64: 546.
18. PARKER W, LUNDBERG-SWANSON KL, HOLZKNECHT ZE, et al. Isohemagglutinins and xenoreactive antibodies: members of a distinct family of natural antibodies. Hum Immunol 1996; 45: 94.
19. PLATT JL, FISCHEL RJ, MATAS AJ, et al. Immunopathology of hyperacute xenograft rejection in a swine to primate model, transplantation 1991; 52: 514.
20. KOREN E, KUJUNDZIC M, KOSCEC M, et al. Cytotoxic effects of human preformed anti-Gal IgG and complement on cultured pig cells. Transplant Proc 1994; 26: 1336.
21. LARSEN RD, RIVERA MC, ERNST LK, et al. Frameshift and non-sense mutations in a human genomic sequence homologous to a murine UDP-Gal:β-D-Gal(1,4)-D-G1cNAcα(1,3)-galactosyltransferase cDNA. J Biol Chem 1990; 265: 7055.
22. JOZIASSE DH, SHAPER JH, JABS EW, et al. Characterization of an α1,3-galactosyltransferase homologue on human chromosome 12 that is organized as a processed pseudogene J Biol Chem 1991; 266: 6991.
23. GALILI U, ANDREWS P. Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates. J Hum Evol 1995; 29: 433.
24. LAMBRIGTS D, SACHS DH, COOPER DKC. Discordant organ xenotransplantation in primates. World experience and current status. Tranplantation 1998; 66: 547.
25. ROSE AG, COOPER DKC, HUMAN PA, et al. Histopathology of hyperacute rejection of the heart: experimental and clinical observations in allografts and xenografts. J Heart Lung Transplant 1991; 10: 223.
26. COOPER DKC, HUMAN PA, LEXER G, et al. Effects of cyclosporine and antibody adsorption on pig cardiac xenograft survival in the baboon. J Heart Lung Transplant 1988; 7: 238.
27. ALEXANDRE GPJ, GIANELLO P, LATINNE D, et al. Plasmapheresis and splenectomy in experimental renal xenotransplantation. In: HARDY MA, ed. Xenograft, 25. New York: , Elsevier, 1989.
28. SABLINSKI T, LATINNE D, GIANELLO P, et al. Xenotransplantation of pig kidneys to nonhuman primates. I. Development of the model. Xeno-transplantation 1995; 2: 264.
29. COOPER DKC, CAIRNS TDH, TAUBE DH. Extracorporeal immunoadsorption of anti-pig antibody in pigs using αGal oligosaccharide immunoaffinity columns. Xenotransplantation 1996; 4: 27.
30. KAPLON RJ, MICHLER RE, XU H, et al. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1994; 59: 1.
31. COLLINS BH, COTTERELL AH, MCCURRY KR, et al. Cardiac xenografts between primate species provide evidence for the importance of the α-galactosyl determinant in hyperacute rejection J Immunol 1995; 154: 5500.
32. LEVENTHAL JR, DALMASSO AP, CROMWELL JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
33. KOBAYASHI T, TANIGUCHI S, NEETHLING FA, et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy Transplantation 1997; 64: 1255.
34. COZZI E, WHITE DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1: 964.
35. MCCURRY KR, KOOYMAN DL, ALVARADO CG, et al. Human complement regulatory proteins protect swine to primate cardiac xenografts from human injury. Nature Med 1995; 1: 123.
36. SCHMOECKEL M, BHATTI FN, ZAIDI A, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570.
37. ZAIDI A, SCHMOECKEL M, BHATTI F, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors Transplantation 1998; 65: 1584.
38. KOZLOWSKI T, MONROY R, XU Y, et al. Anti-Gala1-3Gal antibody response to porcine bone marrow in unmodified baboons and baboons conditioned for tolerance induction. Transplantation 1998; 66: 176.
39. KOZLOWSKI T, SHIMIZU A, LAMBRIGTS D, et al. Porcine kidney and heart transplantation in baboons undergoing a tolerance inducing regimen and antibody adsorption. Transplantation 1999; 67: 18.
40. GROTH CG, KORGSEN O, TIBELL A, et al. Transplantation of fetal porcine pancreas to diabetic patients: Biochemical and histological evidence for graft survival. Lancet 1994; 344: 1402.
41. GALILI U, LATEMPLE DC, WALGENBACH AW, et al. Porcine and bovine cartilage transplants in cynomolgus monkeys: II. Changes in anti-gal response during chronic rejection. Transplantation 1997; 63: 646.
42. GOODMAN DL, MILLAN MT, FERRAN C, et al. Mechanisms of delayed xenograft rejection. In: COOPER DKC, KEMP E, PLATT JL, WHITE DJG, eds. Xenotransplantation, 2nd edn. Heidelberg: Springer, 1997.
43. BUHLER L, FRIEDMAN T, IACOMINI J, COOPER DKC. Xenotransplantation - state of the art - update. Front Biosci 1999; 4: 416.
44. CHOPEK MW, SIMMONS RL, PLATT JL. ABO incompatible renal transplantation: initial immunopathologic evaluation. Transplant Proc 1987; 19: 4553.
45. ALEXANDRE GPJ, SQUIFFLET JP, DE BRUYERE M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc 1987; 19: 4538.
46. PALMER A, WELSH K, GJORSTRUP P, et al. Removal of HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989; 1: 10.
47. BACH FH, PLATT JL, COOPER DKC. Accommodation -the role of natural antibody and complement in discordant xenograft rejection. In: COOPER DKC, KEMP E, REEMTSMA K, WHITE DJG, eds. Xenotransplantation, 1st edn. Heidelberg: Springer, 1991.
48. BACH FH, FERRAN C, HECHENLEITNER P, et al. Accommodation of vascularized xenografts: expression of "protective genes" by donor endothelial cells in a host Th2 cytokine environment. Nature Med 1997; 3: 196.
49. SYKES M, SACHS DH. Xenogeneic tolerance through hematopoietic cell and thymic transplantation. In: COOPER DKC, KEMP E, PLATT JL, WHITE DJG, eds. Xenotransplantation, 2nd edn. Heidelberg: Springer, 1997.
50. MOBERG AW, SHONS AR, GERWURZ H, et al. Prolongation of renal xenografts by the simultaneous sequestration of preformed antibody, inhibition of complement, coagulation, and antibody synthesis. Transplant Proc 1971; 3: 538.
51. SLAPAK M, GREENBAUM M, BARDAWIL W, et al. Effect of heparin, arvin, liver perfusion, and heterologous anti-platelet serum on rejection of pig kidney to dog. Transplant Proc 1971; 3: 558.
52. SHONS AR, BEIR M, JETZER J, et al. Techniques of in vivo plasma modification for the treatment of hyperacute rejection. Surgery 1973; 73: 28.
53. TERMAN DS, GARCIA-RINALDI R, MCCALMON R, et al. Modification of hyperacute renal xenograft rejection after extracorporeal immunoadsorption of heterospecific antibody. Int J Artif Organs 1979; 2: 35.
54. LEXER G, COOPER DKC, ROSE AG, et al. Hyperacute rejection in a discordant (pig-to-baboon) cardiac xenograft model. J Heart Transplant 1986; 5: 411.
55. AZIMZADEH A, MEYER C, WATIER H, et al. Removal of primate xenoreactive natural antibodies by extracorporeal perfusion of pig kidneys and livers. Transplant Immunol 1998; 1: 13.
56. MACCHIARINI P, ORIOL R, AZIMZADEH A, et al. Evidence of human non-alpha-galactosyl antibodies involved in the hyperacute rejection of pig lungs and their removal by pig organ perfusion. J Thorac Cardiovasc Surg 1998; 5: 831.
57. YE Y, NEETHLING FA, NIEKRASZ M, et al. Evidence that intravenously administered alpha-galactosyl carbohydrates reduce baboon serum cytotoxicity to pig kidney cells (PK15): and transplanted pig hearts. Transplantation 1994; 58: 330.
58. TANIGUCHI S, NEETHLING FA, KORCHAGINA EY, et al. In vivo immunoadsorption of antipig antibodies in baboons using a specific Galα1-3Gal column. Transplantation 1996; 10: 1: 379.
59. XU Y, LORF T, SABLINSKI T, et al. Removal of anti-porcine natural antibodies from huma and nonhuman primate plasma 111 vitro and in vivo by a Galα1-3Galb1-4G1c-X immunoaffinity column. Transplantation 1998; 65: 172.
60. KOZLOWSKI T, IERINO FL, LAMBRIGTS D, et al. Depletion of anti-αGal1-3Gal antibody in baboons by specific immunoaffinity columns. Xenotransplantation 1998; 5: 122.
61. KOREN E, MILOTIC F, NEETHLING FA, et al. Monoclonal antiidiotypic antibodies neutralize cytotoxic effects of anti-αGal antibodies. Transplantation 1996; 62: 837.
62. WORDELL CJ. Use of intravenous immune globulin therapy: an overview. DICP 1991; 25: 805.
63. JORDAN SC, TYAN D, CZER L, et al. Immunomodulatory actions of intravenous immunoglobulin (IVIG): potential applications in solid organ transplant recipients. Pediatr Transplant 1998; 2: 92.
64. MAGEE JC, COLLINS BH, HARLAND RC, et al. Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation. J Clin Invest 1995; 96: 2404.
65. YU Z, LENNON VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227.
66. NEETHLING FA, JOZIASSE D, BOVIN N, et al. The reducing end of αGal oligosaccharides contributes to their efficiency in blocking natural antibodies of human and baboon sera. Transplant Int 1996; 9: 98.
67. SIMON PM, NEETHLING FA, TANIGUCHI S, et al. Intravenous infusion of αGal oligosaccharides in baboons delays hyperacute rejection of porcine heart xenografts. Transplantation 1998; 63: 346.
68. ROMANO E, NEETHLING FA, NILSSON KGI, et al. Intravenous synthetic αGal saccharides delay hyperacute rejection following pig-to-baboon heart transplantation Xenotransplantation 1996; 6: 36.
69. LINDSLEY K, DEEG HJ. Total body irradiation for marrow or stem-cell transplantation. Cancer Invest 1998; 16: 424.
70. KIMIKAWA M, KAWAI T, SACHS DH, et al. Mixed chimerism and transplantation tolerance induced by a nonlethal preparative regimen in cynomolgus monkeys Transplant Proc 1997; 29: 1218.
71. CLAVE E, SOCIE G, COSSET JM. Multicolor flow cytometry analysis of blood cell subsets in patients given total body irradiation before bone marrow transplantation. Int J Radiat Oncol Biol Phys 1995; 34: 881.
72. LAMBRIGTS D, VAN CALSTER P, Xu Y, et al. Pharmacologic immunosuppressive therapy and extracorporeal immunoadsorption in the suppression of anti-αGal antibody in the baboon. Xenotransplantation 1998; 5: 274.
73. MINANOV OP, ARTRIP JH, SZABOLCS M, et al. Triple immunosuppression reduces mononuclear cell infiltration and prolongs graft life in pig-to-newborn baboon cardiac xenotransplantation. J Thorac Cardiovasc Surg 1998; 115: 998.
74. LINDBACK S, VIZZARD J, COOPER DA, et al. Long-term prognosis following zidovudine monotherapy in primary human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179: 1549.
75. COSTANZO-NORDIN M, GRUSK B, SILVER M, et al Reversal of recalcitrant cardiac allograft rejection with methotrexate. Circulation 1988; 78: 47.
76. GORSKI A, GRIEB P, KORCZAK-KOWALSKA G, et al. Cladribine, 2-chloro-deoxyadenosine (CDA): an inhibitor of human B and T cell activation in vitro. Immunopharmacology 1993; 26: 197.
77. REFF ME, CARNER K, CHAMBERS KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435.
78. MALONEY DG, GRILLO-LOPEZ AJ, BODKIN DJ, et al. IDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266.
79. TOBINAI K, KOBAYASHI Y, NARABAYASHI M, et al. Feasibility and pharmacokinitic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in relapsed B cell lymphoma. The IDEC-C2B8 study group. Ann Oncol 1998; 9: 527.
80. COIFFIER B, HAIOUN C, KETTERER N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927.
81. MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program. J Clin Oncol 1998; 16: 2825.
82. BOLOGNESSI A, TAZZARI PL, OLIVIERI F, et al. Evaluation of immunotoxin containing single-chain ribosome-inactivating proteins and an anti-CD22 monoclonal antibody (OM124): in vitro and in vivo studies. Br J Haematol 1998; 101: 179.
83. SAUSVILLE EA, HEADLEE D, STETLER-STEVENSON M, et al. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B cell lymphoma: a phase I study. Blood 1995; 85: 3457.
84. TEDDER TF, TUSCANO J, SATO S, et al. CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling. Annu Rev Immunol 1997; 15: 481.
85. ARMITAGE RJ, FANSLOW WC, STROCKBINE L, et al. Molecular and biological characterization of a murine ligand for CD40. Nature 1992; 357: 80.
86. NOELLE R, ROY M, SHEPHERD D, et al. A 39-kDa protein on activated helper T cells binds CD40and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci USA 1992; 89: 6550.
87. LARSEN CP, ELWOOD ET, ALEXANDER DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 ligand. Nature 1996; 381: 434.
88. KIRK AD, HARLAN DM, ARMSTRONG NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789.
89. WEKERLE T, SAYEGH MH, HILL J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037.
90. ELWOOD ET, LARSEN CP, CHO HR, et al. Prolonged acceptance of concordant and discordant xenografts with combined CD40 and CD28 pathway blockade. Transplantation 1998; 65: 1422.
91. BUHLER L, AWWAD M, BASKER M, et al. High-dose porcine hematopoietic cell transplantation combined with CD40 ligand blockade in baboons prevents an induced anti-pig humoral response. (Personal communication).
92. BOUHOURS D, POURCEL C, BOUHOURS JF. Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Galα1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Glycoconjugate J. 1996; 13: 947.